Lesia Kurlak (staff)

From: nottingham2.rec@hra.nhs.uk <noreply@harp.org.uk>

Sent: 09 April 2024 13:16

To: Christine Roffe; MS-MAPS-2

Subject: IRAS Project ID 290474. HRA and HCRW Approval for the Amendment

You don't often get email from noreply@harp.org.uk. Learn why this is important

Dear Professor Roffe,

IRAS Project ID:	290474
Short Study Title:	Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial
Amendment No./Sponsor Ref:	290474_MA_18_24
Amendment Date:	20 March 2024
Amendment Type:	Non Substantial CTIMP

I am pleased to confirm HRA and HCRW Approval for the above referenced amendment.

You should implement this amendment at NHS organisations in England and Wales, in line with the guidance in the amendment tool.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/.

Please contact amendments@hra.nhs.uk for any queries relating to the assessment of this amendment.

Kind regards

Bethany Spittlehouse

Health Research Authority

2nd Floor | 2 Redman Place | Stratford | London | E20 1JQ

E.amendments@hra.nhs.uk

W. www.hra.nhs.uk

Sign up to receive our newsletter HRA Latest